Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
Natera CEO Steve Chapman has received two significant recognitions in 2024: being named one of the top healthcare technology CEOs by Healthcare Technology Report and 'BioTechnology Innovator of the Year' by BioTech Breakthrough Awards. During his 15-year tenure at Natera, including serving as CEO since 2019, the company has published over 250 peer-reviewed papers and launched 20 products that have transformed patient care.
Under Chapman's leadership, Natera has developed key products including the Signatera™ oncology test, Prospera™ transplant assessment test, and Panorama™ non-invasive prenatal test. The Healthcare Technology Report's annual program recognizes the top 50 CEOs in biotechnology and life sciences, while the BioTech Breakthrough Awards received nominations from over 14 countries globally.
Il CEO di Natera, Steve Chapman, ha ricevuto due importanti riconoscimenti nel 2024: è stato nominato uno dei migliori CEO nel settore della tecnologia sanitaria dal Healthcare Technology Report e 'Innovatore Biotecnologico dell'Anno' dai BioTech Breakthrough Awards. Durante il suo mandato di 15 anni in Natera, di cui è CEO dal 2019, l'azienda ha pubblicato oltre 250 articoli peer-reviewed e lanciato 20 prodotti che hanno trasformato l'assistenza ai pazienti.
Sotto la guida di Chapman, Natera ha sviluppato prodotti chiave tra cui il test oncologico Signatera™, il test di valutazione dei trapianti Prospera™ e il test prenatale non invasivo Panorama™. Il programma annuale del Healthcare Technology Report riconosce i 50 migliori CEO nel campo della biotecnologia e delle scienze della vita, mentre i BioTech Breakthrough Awards hanno ricevuto nomination da oltre 14 paesi in tutto il mondo.
El CEO de Natera, Steve Chapman, ha recibido dos reconocimientos significativos en 2024: fue nombrado uno de los mejores CEOs en tecnología de salud por Healthcare Technology Report y 'Innovador Biotecnológico del Año' por los BioTech Breakthrough Awards. Durante su periodo de 15 años en Natera, incluyendo su tiempo como CEO desde 2019, la compañía ha publicado más de 250 artículos revisados por pares y lanzado 20 productos que han transformado la atención al paciente.
Bajo el liderazgo de Chapman, Natera ha desarrollado productos clave incluyendo la prueba oncológica Signatera™, la prueba de evaluación de trasplantes Prospera™ y la prueba prenatal no invasiva Panorama™. El programa anual del Healthcare Technology Report reconoce a los 50 mejores CEOs en biotecnología y ciencias de la vida, mientras que los BioTech Breakthrough Awards recibieron nominaciones de más de 14 países en todo el mundo.
나테라 CEO 스티브 차프먼은 2024년에 두 가지 중요한 인정을 받았습니다: 헬스케어 기술 보고서에서 기술 헬스케어 분야 최고의 CEO 중 한 명으로 선정되었고, 올해의 생명공학 혁신가로 BioTech Breakthrough Awards에서 선정되었습니다. 2019년부터 CEO로 재직하며 나테라에서 15년의 경력을 쌓은 그는 250편 이상의 동료 검토 논문을 발표하고 20개 제품을 출시하여 환자 치료를 혁신했습니다.
차프먼의 리더십 아래 나테라는 Signatera™ 종양학 테스트, Prospera™ 이식 평가 테스트 및 Panorama™ 비침습적 임신 테스트와 같은 핵심 제품을 개발했습니다. 헬스케어 기술 보고서의 연례 프로그램은 생명공학 및 생명 과학 분야의 50대 CEO를 인정하며, BioTech Breakthrough Awards는 전 세계 14개국 이상의 후보가 추천되었습니다.
Le PDG de Natera, Steve Chapman, a reçu deux reconnaissances significatives en 2024 : il a été nommé l'un des meilleurs PDG dans le domaine de la technologie de la santé par le Healthcare Technology Report et 'Innovateur Biotechnologique de l'Année' par les BioTech Breakthrough Awards. Au cours de ses 15 ans chez Natera, dont 2019 en tant que PDG, l'entreprise a publié plus de 250 articles évalués par des pairs et lancé 20 produits qui ont transformé les soins aux patients.
Sous la direction de Chapman, Natera a développé des produits clés, notamment le test oncologique Signatera™, le test d'évaluation des transplantation Prospera™ et le test prénatal non invasif Panorama™. Le programme annuel du Healthcare Technology Report reconnaît les 50 meilleurs PDG en biotechnologie et en sciences de la vie, tandis que les BioTech Breakthrough Awards ont reçu des nominations de plus de 14 pays dans le monde.
Natera CEO Steve Chapman hat 2024 zwei bedeutende Auszeichnungen erhalten: Er wurde von Healthcare Technology Report als einer der besten CEOs im Bereich Gesundheitstechnologie ausgezeichnet und als 'Biotechnologie-Innovator des Jahres' von den BioTech Breakthrough Awards geehrt. In seinen 15 Jahren bei Natera, davon seit 2019 als CEO, hat das Unternehmen über 250 peer-reviewed Veröffentlichungen veröffentlicht und 20 Produkte auf den Markt gebracht, die die Patientenversorgung revolutioniert haben.
Unter Chapmans Führung hat Natera Schlüsselprodukte entwickelt, darunter den onkologischen Test Signatera™, den Transplantationsbewertungstest Prospera™ und den nicht-invasiven pränatalen Test Panorama™. Das jährliche Programm des Healthcare Technology Report erkennt die 50 besten CEOs in der Biotechnologie und Lebenswissenschaften an, während die BioTech Breakthrough Awards Nominierungen aus über 14 Ländern weltweit erhalten haben.
- None.
- None.
Steve Chapman, CEO, Natera (Photo: Business Wire)
During Chapman’s 15-year tenure at Natera, the company has published more than 250 peer-reviewed papers and launched 20 products that have transformed patient care, including two of the fastest growing genetic tests of all time. The company’s suite of products includes the Signatera™ oncology test for molecular residual disease; the Prospera™ transplant assessment test; and the highly differentiated Panorama™ test serving patients in the non-invasive prenatal testing market.
“I want to congratulate every team member at Natera for their contributions in helping us achieve this award,” said Steve Chapman, CEO. “Innovation is core to our mission of transforming disease management for millions of patients worldwide, and we are honored to help individuals and families as they navigate some of life’s most important healthcare journeys.”
The annual awards program by Healthcare Technology Report features the top 50 CEOs at influential biotechnology and life sciences companies. These leaders have brought some of the most advanced healthcare solutions to market, leveraging keen business acumen while improving the patient care experience and outcomes.
BioTech Breakthrough is a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe. The mission of the annual awards program is to conduct the industry’s most comprehensive analysis and evaluation of the world’s top companies, solutions, and products in the life sciences and biotechnology markets today. This year’s program attracted thousands of nominations from over 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.
Steve Chapman: Biographical Information
Steve Chapman is the chief executive officer of Natera, a global leader in cell-free DNA and genetic testing in oncology, women’s health, and organ health. He also serves on the company’s board of directors.
Chapman is a leading authority on the commercialization of genetic testing. Before his appointment as CEO in 2019, he held a number of other leadership positions at Natera including chief operating officer. Earlier in his career, he worked at Genzyme Genetics. He began his career as a researcher in the department of human genetics at the University of California Los Angeles (UCLA), where he designed arrays identifying SNPs associated with multiple sclerosis.
Chapman has been a guest on CNBC and other shows and podcasts to share more about Natera’s impact on patient care in the field of personalized genetic testing and diagnostics. He is an author on multiple scientific papers.
Chapman graduated with honors and holds a B.S. in Microbiology, Immunology, and Molecular Genetics from UCLA.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250117320339/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
FAQ
What major awards did Natera (NTRA) CEO Steve Chapman receive in 2024?
How many products has Natera (NTRA) launched under Steve Chapman's leadership?
What are the main diagnostic products offered by Natera (NTRA)?
How many peer-reviewed papers has Natera (NTRA) published during Chapman's tenure?
What is the scope of the BioTech Breakthrough Awards that recognized Natera's CEO?
